“We are talking to more than one of the larger pharmaceutical companies about the possibility of outlicensing our treatment,” Aberman said by phone from Boston. “We are not under pressure as we are sitting on about $40 million in cash, but if the deal is good enough, we’ll take it.”
3 months later.....secondary. The only liar is Zami.......
Sorry, I was wrong, the article was from June, not May 2012. Gotta stop hitting the pipe so early in the am....lol
Funny how Zami has been talking licensing agreement since a May 2012 Bloomberg interview. Nothing yet. The best executive change they could make would be to force Zami out. He's no good for the company.
If PPS has doubled in about 2 years, while dilution is up 20-30%, I think Zami is doing the correct thing progressing the technology, increasing market cap, and making this "more saleable" for licensing, etc. More shares makes more sense.